New KRAS-Targeted Therapy Shows Early Promise for Lung and Pancreatic Cancer

A new KRAS-targeted therapy is showing encouraging early results for patients with advanced lung and pancreatic cancer. In this episode, we break down the latest clinical trial findings and explain what this experimental treatment could mean for patients with KRAS G12D mutations. You’ll learn: What the KRAS G12D mutation is and why it matters in cancer care Why KRAS mutations have been difficult to target for decades How does this new targeted therapy work differen...